ClinicalTrials.gg
RecruitingNCT04621357COPITCHUpdated Apr 22, 2026

Influence of Cerebral Oedema in Intracerebral Haemorrhage

An interventional study of Brain MRI and Biological biomarkers in Stroke and Intra Cerebral Hemorrhage, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Stroke by University Hospital, Lille — 4 open to participants now, 4 under way, none of them phase 3. Stroke · University Hospital, Lille.

Started
2021
the only one that year
No phase
7 of 15
2 open now
Registered
11th of 15
by date

Among the 15 studies in Stroke by University Hospital, Lille, this one is the only one that started in 2021, is one of 7 with no phase, and was the 11th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 15 studies in Stroke by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Stroke by University Hospital, Lille, or all of them as a file.
02

Study summary

In 2020, IntraCerebral Haemorraghe (ICH) remains the most devastating type of stroke. Besides stroke unit care, no specific treatment has been proven effective yet. Perihaematomal oedema (PHO) could be a promising therapeutic target. However, the mechanisms, the natural history as well as the clinical impact of this PHO remain unclear. The COPITCH study has been designed to answer these questions

03

Conditions studied

  • Stroke
  • Intra Cerebral Hemorrhage

Keywords

  • Intra Cerebral Hemorrhage
  • Perihaematomal oedema
  • MRI
  • outcome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With a spontaneous ICH, i.e. non traumatic
  • Admitted within 12 hours of stroke onset. For wake-up strokes, time of last seen well will be considered as stroke onset
  • Patient insured under the French social security
  • Consent form signed

Exclusion criteria

Exclusion Criteria:

  • Pure intraventricular haemorrhages
  • "secondary" ICH: ICH resulting from intracranial vascular malformation, intracranial venous thrombosis, head trauma or tumour; haemorrhagic transformation within an infarct
  • Pre-admission modified Rankin score of 4 or 5
  • of less than 1 year related to comorbidities (end stage cancer, end stage organ failure)
  • Pregnancy or breastfeeding or Women of childbearing age without effective (a pregnancy test will be done)
  • Adults who are deprived of their liberty by judicial or administrative decision
  • Referral from other hospitals
  • to MRI : claustrophobia, ocular metallic foreign bodies (accidental or other) or in a risk area (nervous or vascular system);irremovable implanted medical device (pacemaker, neurostimulator, cochlear implants and others);metallic heart valve (mainly old heart valves) or vascular clips previously implanted on cranial aneurysms; gadolinium allergy
  • No consent form
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Patient with intracerebral haemorrhage

    Patients will be screened at admission in the stroke units right after brain MRI demonstrating the presence of blood in the brain parenchyma.

    Radiation: Brain MRI · Biological: Biological biomarkers

Interventions

  • RadiationBrain MRI

    Brain MRI will include differents sequences.

  • BiologicalBiological biomarkers

    Biological biomarkers will include a set of systemic inflammatory markers

06

What researchers measure

Primary outcomes

  1. Poor functional outcome defined as a modified Rankin Scale of 4 or more

    Time frame: at 3 months

Secondary outcomes

  1. overall distribution of the modified Rankin scale at 3- and 12 months

    The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.

    Time frame: at 3 months and 12 months

  2. Early neurological deterioration defined as more than 4 points on the NIHSS score

    The NIHSS score (NIH Stroke Scale) is used to monitor the progression of an ischemic or hemorrhagic stroke. It is rated from 0 to 42 points. Depending on the result, a distinction is made from Minor stroke to Severe stroke

    Time frame: at 96 hours

  3. all-cause mortality at 3 and 12 months

    Time frame: at 3 and 12 months

  4. Cognitive decline

    Cognitive decline defined as a score on MOCA test below 27

    Time frame: at 3 months, at 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Dec 2027, 77 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 77 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2020
First posted
Nov 9, 2020
StartActual
Jun 4, 2021
Primary completionEst.
Dec 3, 2027
CompletionEst.
Dec 3, 2027
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04621357
Collaborators
Conseil Régional Hauts-de-France, France, Fondation pour la recherche sur les AVC
Responsible party
Sponsor
First posted
Nov 9, 2020
Start date
Jun 4, 2021
Primary completion
Dec 3, 2027 (estimated)
Completion
Dec 3, 2027 (estimated)
Last update
Apr 22, 2026

Study contacts

Charlotte Cordonnier, MD,PhD
Contact
charlotte.cordonnier@chu-lille.fr
0320445962 ext. +33
Charlotte Cordonnier, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion